DCA is a long known drug, usually involved in the treatment of rare congenital metabolic disorders. Interestingly, the metabolic disorders mentioned show a very similar cell metabolism to the one found in cancer cells. Several clinical trials and studies prove the value of DCA as an anti cancer drug. So far, two important effects have been discovered that explain why DCA is a potent agent in cancer therapy. In cancer cells, DCA deprives the organic construction material needed for further cell division. In addition it disinhibits apoptotic pathways, leaving the cancer cell in a rather vulnerable condition. As many other approaches aim to activate apoptosis in the cancer cells, DCA acts as a general booster for such procedures. While oral medication bears the risk of a reversible neuropathy, intravenous administration turned out to be as well safe and effective.